Source: Clinical Trials Arena

Cardurion: Cardurion begins subject dosing in Phase II heart failure trial

CARDINAL-HF is said to be the first Phase II proof-of-concept trial of a PDE9 inhibitor in heart failure. The post Cardurion begins subject dosing in Phase II heart failure trial appeared first on Clinical Trials Arena.

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
1-25
Agree?
Peter S. Lawrence's photo - President & CEO of Cardurion

President & CEO

Peter S. Lawrence

CEO Approval Rating

88/100

Read more